← KalVista Pharmaceuticals, Inc. (KALV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
KalVista Pharmaceuticals, Inc. (KALV)
Pharmaceutical Preparations · market cap $1.4B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-08-31 (est.)
Phase 3
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
KalVista Pharmaceuticals (KALV) is a clinical-stage pharma with 270 employees and a ~$1.44B market cap, focused primarily on oral plasma kallikrein inhibitors for Hereditary Angioedema (HAE). Its lead asset, KVD900 300 mg, is in Phase 3 for HAE, with a 600 mg dose also in Phase 3; a separate injectable asset (KVD001) is in Phase 2 for Diabetic Macular Edema. The company holds $213.8M in cash with a stated 44-month runway, but burns are accelerating — net loss widened to $183M in fiscal 2025.
The catalyst path
- 2027-08-31 (est.)Phase 3 · KVD900 600 mgimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| KVD900 300 mg | Phase 3 | Hereditary Angioedema |
| KVD900 600 mg | Phase 3 | Hereditary Angioedema |
| KVD001 Injection | Phase 2 | Diabetic Macular Edema |
| KVD900 | Phase 2 | Hereditary Angioedema |
Price & technical context
3-month
+56.1%
6-month
+64.6%
12-month
+82.9%
52-wk range
$10.76–$27.00
vs 50-day MA
+14.0%
vs 200-day MA
+61.6%
Realized vol
80.9%
Max drawdown
-51.9%
Daily closes through 2026-06-10. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KALV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.